Sanofi to mull riliprubart’s future after stopping late-stage nerve disease study

June 10, 2026 06:37 AM EDT R&D Sanofi to mull riliprubart’s fu­ture af­ter stop­ping late-stage nerve dis­ease study Ayisha Sharma News Reporter Sanofi is end­ing a Phase 3 tri­al of its an­ti­body drug in a rare neu­ro­log­i­cal dis­or­der af­ter an in­de­pen­dent com­mit­tee said the study was un­like­ly … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER